Açaí Extracts in Human Hepatocytes: Cytotoxicity and Modulation of Drug Metabolism Pathways

Study Background and Research Question

Botanical dietary supplements (BDS) are widely consumed for their perceived health benefits, with açaí (Euterpe oleracea) among the most popular for its antioxidant and anti-inflammatory properties. While the global BDS market continues to expand—expected to reach $300 billion by 2028—the safety and regulatory oversight of such products remain limited. A critical concern is the potential for botanical-drug interactions, particularly when botanicals modulate hepatic enzymes or drug transporters crucial to pharmacokinetics. Despite açaí's widespread use, evidence on its capacity to influence cytochrome P450 (CYP450) enzymes or membrane transporters in human hepatocytes is sparse. This knowledge gap motivated the current study, which asks: Do commonly consumed açaí extracts exhibit cytotoxic effects or alter the expression and function of major hepatic drug-metabolizing enzymes and transporters?

Key Innovation from the Reference Study

The reference study by Raichura et al. provides a comprehensive in vitro assessment of açaí extracts' cytotoxicity and their induction potential on key hepatic enzymes and transporters. Unlike prior studies focusing narrowly on antioxidant properties or general cell viability, this work systematically evaluated multiple extract types (aqueous, acidic methanol, methanol, ethanol) sourced from both açaí berry powders and commercial capsules. Furthermore, it incorporated physiologically relevant sandwich-cultured human hepatocytes to model the hepatic environment, and used both gene expression (RT-qPCR) and functional assays to scrutinize effects on CYP1A2, CYP2B6, CYP3A4, P-glycoprotein (P-gp), and organic anion transporting polypeptides (OATP1B1/B3). This multifaceted approach enhances the translational relevance of the findings for predicting potential botanical-drug interactions.

Methods and Experimental Design Insights

The authors selected a diverse panel of açaí extracts representative of consumer products: aqueous, acidic methanol, methanol, and ethanol extracts from both bulk berry powder and commercial capsules. Human sandwich-cultured hepatocytes served as the primary model for cytotoxicity and mRNA induction studies, while LS174T human colon carcinoma cells provided a complementary system for preliminary transporter activity assays. Cytotoxicity was measured using the CellTiter-Glo® luminescent cell viability assay, enabling sensitive quantification of ATP as a proxy for viable cells. For induction studies, hepatocytes were treated with each extract, and changes in CYP450 and transporter mRNA expression were quantified by RT-qPCR. Functional activity of P-gp and OATP transporters was further explored by measuring the intracellular accumulation of selective probe compounds.

Protocol Parameters

• Açaí extract preparation: Use aqueous, acidic methanol, methanol, or ethanol; source from both berry powder and commercial capsules for translational relevance.
• Cell culture: Employ sandwich-cultured human hepatocytes for both cytotoxicity and induction assays.
• Cytotoxicity assessment: Apply CellTiter-Glo® assay after exposure to açaí extracts at varying concentrations and timepoints to capture dose- and time-dependence.
• Induction analysis: Quantify CYP1A2, CYP2B6, CYP3A4, P-gp, and OATP1B1/B3 mRNA expression by RT-qPCR post-treatment.
• Transporter function: For preliminary activity screening, use LS174T cells and monitor probe substrate accumulation to detect changes in P-gp and OATP activity.

Core Findings and Why They Matter

The study found that certain açaí extracts, particularly those prepared with acidic methanol and methanol solvents, led to a dose- and time-dependent decrease in hepatocyte viability. These effects were most pronounced with MRAC (acidic methanol) and MRME (methanol) extracts, as well as MRET (ethanol) and F4AC (acidic methanol from commercial capsules). Importantly, despite these cytotoxic effects at higher concentrations, none of the tested extracts significantly induced mRNA expression of CYP1A2, CYP2B6, CYP3A4, P-gp, or OATP1B1/B3 in human hepatocytes. Functional transporter assays in LS174T cells further supported these findings, showing minimal impact of açaí extracts on the activity of major efflux and uptake transporters. These results suggest that, at typical exposure levels, açaí supplements are unlikely to precipitate significant pharmacokinetic interactions via hepatic enzyme or transporter induction, though high concentrations may pose cytotoxicity risks. This comprehensive approach clarifies the safety margin and interaction potential of açaí products, which is crucial for researchers and clinicians assessing supplement-drug co-administration risks.

Comparison with Existing Internal Articles

Prior resources such as "Açaí Extracts: Cytotoxicity and Enzyme Induction in Human Hepatocytes" provide a focused overview of the cytotoxicity and enzyme induction risks associated with açaí. The present study deepens this knowledge by expanding the panel of extracts tested and integrating both gene expression and functional assays, confirming and extending earlier conclusions. In the context of cholesterol biosynthesis inhibition and drug-transporter modulation research, studies on Pravastatin sodium and its precise inhibition of HMG-CoA reductase offer a gold standard for evaluating metabolic and transporter-mediated effects. By contrast, the current açaí study demonstrates that botanical extracts, at realistic concentrations, do not mimic the strong induction or inhibition effects observed with pharmacological agents like pravastatin sodium, emphasizing the importance of compound specificity in interpreting BDS-drug interaction risk.

Limitations and Transferability

While the study offers robust in vitro data, several limitations should be recognized. The use of primary human hepatocytes and cancer cell lines, though physiologically relevant, cannot fully capture the complexity of in vivo metabolism, inter-individual variability, or chronic exposure scenarios. The functional transporter assays were preliminary and may not reflect subtle modulatory effects detectable in more sensitive or prolonged studies. Furthermore, the cytotoxicity observed at higher extract concentrations may not directly translate to in vivo exposure levels achieved through dietary supplementation. Thus, while the findings inform risk assessment and regulatory discussions, their transferability to clinical practice warrants cautious interpretation and further validation in animal or human studies.

Research Support Resources

For researchers investigating hepatic metabolism, drug transporter modulation, or cholesterol biosynthesis inhibition, precise chemical tools are essential. Pravastatin sodium (SKU A4369) is a highly selective and competitive HMG-CoA reductase inhibitor frequently employed to model cholesterol biosynthesis inhibition and LDL cholesterol reduction in both cell-based and in vivo models. Its well-characterized pharmacological profile and selectivity provide a strong benchmark for interpreting botanical extract effects on hepatic metabolic pathways. APExBIO offers detailed product information to support rigorous experimental workflows in this area.